Literature DB >> 11465749

The phospholipase A2 inhibitor quinacrine prevents increased immunoreactivity to cytoplasmic phospholipase A2 (cPLA2) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection.

X R Lu1, W Y Ong, B Halliwell.   

Abstract

The distribution of cytoplasmic phospholipase A2 (cPLA2), 4-hydroxynonenal (HNE), and choline acetyltransferase (ChAT) was studied in the septum and hippocampus of rats at various time intervals after fimbria-fornix (FF) transection. Very little cPLA2 or HNE immunoreactivity was observed in the normal medial or lateral septum, whereas a large increase in immunoreactivity with both antibodies was observed in the lateral septum one week after transection. The increase in cPLA2 or HNE staining in the lateral septum after FF transection was completely blocked by intraperitoneal injections (once daily) of a lipophilic inhibitor of phospholipase A2, quinacrine (5 mg/kg), showing the importance of phospholipase A2 in generation of arachidonic acid, which is a target for lipid peroxidation and formation of 4-hydroxynonenal. Quinacrine prevented not only a rise in HNE immunoreactivity, but also a rise in cPLA2 immunoreactivity, showing that cPLA2 expression itself is depressed by the drug, in addition to its well-known effect on blocking the catalytic action of phospholipase A2. No increase in cPLA2 or HNE immunoreactivity was observed in neurons of the medial septum after fimbria-fornix transection, even though these showed a decrease in ChAT staining after the lesion. This suggests that glutamate released from transected hippocamposeptal afferents or increased activity of the supramammillary area following FF transection may lead to increased cPLA2 and HNE immunreactivity, whereas retrograde degeneration in neurons may not. We conclude that there is free-radical damage, as evidenced by HNE formation in neurons of the lateral septum after fimbria-fornix transection, and that this increase in HNE is dependent on phospholipase A2 activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465749     DOI: 10.1007/s002210100737

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  6 in total

1.  Reactivation of the Epstein-Barr virus from viral latency by an S-adenosylhomocysteine hydrolase/14-3-3 zeta/PLA2-dependent pathway.

Authors:  Diana Maas; Claudine Maret; Lars Schaade; Simone Scheithauer; Klaus Ritter; Michael Kleines
Journal:  Med Microbiol Immunol       Date:  2006-06-21       Impact factor: 3.402

2.  Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila.

Authors:  Abrar Qurashi; Huijie Liu; Laurie Ray; David L Nelson; Ranhui Duan; Peng Jin
Journal:  Hum Mol Genet       Date:  2012-02-01       Impact factor: 6.150

3.  Secretory phospholipase A2 activity in the normal and kainate injected rat brain, and inhibition by a peptide derived from python serum.

Authors:  M-M Thwin; W-Y Ong; C-W Fong; K Sato; K Kodama; A A Farooqui; P Gopalakrishnakone
Journal:  Exp Brain Res       Date:  2003-04-18       Impact factor: 1.972

4.  Characterizing phospholipase A2-induced spinal cord injury-a comparison with contusive spinal cord injury in adult rats.

Authors:  Nai-Kui Liu; William Lee Titsworth; Yi Ping Zhang; Aurela I Xhafa; Christopher B Shields; Xiao-Ming Xu
Journal:  Transl Stroke Res       Date:  2011-12-01       Impact factor: 6.829

Review 5.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

Review 6.  Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications.

Authors:  Wei-Yi Ong; Mei-Lin Go; De-Yun Wang; Irwin Kee-Mun Cheah; Barry Halliwell
Journal:  Mol Neurobiol       Date:  2020-09-08       Impact factor: 5.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.